---
schema_version: "secwatch.filing_event.v1"
accession: "0001297184-22-000036"
form_type: "8-K"
ticker: "AMPH"
cik: "0001297184"
company_name: "Amphastar Pharmaceuticals, Inc."
filed_at: "2022-07-08T23:59:59+00:00"
generated_at: "2026-06-24T18:07:28.034836+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Amphastar enters $2.2M R&D agreement with related party Hanxin for insulin cell banks

## Summary
- Agreement with Nanjing Hanxin to develop Recombinant Human Insulin Research Cell Banks (RCBs) and provide exclusive worldwide license.
- Total cost capped at ~$2.2M; initial payment ~$0.2M; payments in Chinese yuan.
- Related party: CEO Jack Zhang & Chairman Mary Luo family own majority of Hanxin; approved by independent Audit Committee.
- Agreement term three years; Amphastar owns all title to RCBs and related IP.

## SEC filing metadata
- accession: 0001297184-22-000036
- form_type: 8-K
- ticker: AMPH
- cik: 0001297184
- company_name: Amphastar Pharmaceuticals, Inc.
- filed_at: 2022-07-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1297184/000129718422000036/0001297184-22-000036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1297184/000129718422000036/amph-20220705x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001297184-22-000036
- JSON: https://secwatch.observer/filing/0001297184-22-000036.json
- Plain text: https://secwatch.observer/filing/0001297184-22-000036.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.